147 related articles for article (PubMed ID: 37187018)
21. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
22. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
24. Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy.
Tan Q; Qin Q; Huang Z; Lian B; Mo Q; Wei C
Breast Cancer Res Treat; 2022 Jun; 193(2):393-403. PubMed ID: 35304903
[TBL] [Abstract][Full Text] [Related]
25. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
26. Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer.
Hong J; Rui W; Fei X; Chen X; Shen K
Cancer Med; 2021 Nov; 10(22):7921-7933. PubMed ID: 34562054
[TBL] [Abstract][Full Text] [Related]
27. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
[TBL] [Abstract][Full Text] [Related]
28. Real‑world data indicated that neoadjuvant chemotherapy alone was associated with a higher risk of tumor recurrence in high‑risk breast cancer subgroup patients.
Li Z; Li Y; Liu Y; Shang Y; Zhou Y; Ji X; Han H; Du K; Zhang J
Oncol Lett; 2023 May; 25(5):193. PubMed ID: 37113400
[TBL] [Abstract][Full Text] [Related]
29. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.
LeVasseur N; Sun J; Gondara L; Diocee R; Speers C; Lohrisch C; Chia S
J Cancer Res Clin Oncol; 2020 Feb; 146(2):529-536. PubMed ID: 31741041
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
Bagegni NA; Tao Y; Ademuyiwa FO
PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
[TBL] [Abstract][Full Text] [Related]
33. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
Li C; Fan H; Xiang Q; Xu L; Zhang Z; Liu Q; Zhang T; Ling J; Zhou Y; Zhao X; Cui Y
Breast Cancer Res Treat; 2019 Dec; 178(3):497-504. PubMed ID: 31471838
[TBL] [Abstract][Full Text] [Related]
36. Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer.
Pastoriza JM; Karagiannis GS; Lin J; Lanjewar S; Entenberg D; Condeelis JS; Sparano JA; Xue X; Rohan TE; Oktay MH
Clin Exp Metastasis; 2018 Oct; 35(7):613-623. PubMed ID: 30136072
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
39. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
40. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
